The disposition kinetics of six cationic drugs in perfused diseased and normal rat livers were determined by multiple indicator dilution and related to the drug physicochemical properties and liver histopathology. A carbon tetrachloride (CCl 4 )-induced acute hepatocellular injury model had a higher fibrosis index (FI), determined by computer-assisted image analysis, than did an alcohol-induced chronic hepatocellular injury model. The alcohol-treated group had the highest hepatic ␣ 1 -acid glycoprotein, microsomal protein (MP), and cytochrome P450 (P450) concentrations. Various pharmacokinetic parameters could be related to the octanol-water partition coefficient (log P app ) of the drug as a surrogate for plasma membrane partition coefficient and affinity for MP or P450, the dependence being lower in the CCl 4 -treated group and higher in the alcohol-treated group relative to controls. Stepwise regression analysis showed that hepatic extraction ratio, permeabilitysurface area product, tissue-binding constant, intrinsic clearance, partition ratio of influx (k in ) and efflux rate constant (k out ), and k in /k out were related to physicochemical properties of drug (log P app or pK a ) and liver histopathology (FI, MP, or P450). In addition, hepatocyte organelle ion trapping of cationic drugs was evident in all groups. It is concluded that fibrosis-inducing hepatic disease effects on cationic drug disposition in the liver may be predicted from drug properties and liver histopathology.
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It is well established that liver disease alters hepatic microcirculation (Varin and Huet, 1985) and impairs the disposition kinetics of many solutes, including drugs (Reichen et al., 1987; Gariepy et al., 1993) . Callaghan et al. (1993) and Morgan and McLean (1995) have suggested that hypoxia, changes in enzyme activity, and alterations in plasma and intrahepatocellular proteins (albumin and ␣ 1 -acid glycoprotein) during liver disease may influence the hepatic disposition of drugs. Fenyves et al. (1993) have also postulated that the disposition of propranolol in cirrhosis is dependent, in part, on capillarization and intrahepatic shunts, oxygen delivery, and possibly acinar heterogeneity. Furthermore, induced pharmacokinetic changes due to liver disease also depend on drug properties (low or high hepatic extraction, extent of protein binding, etc.) as well as on the severity of liver disease (Rodighiero, 1999) . At present, there appears to be no work quantitatively relating hepatic pharmacokinetics to both the drug properties and hepatic pathophysiology (Morgan and McLean, 1995) .
In this work, we attempt to define the hepatic pharmacokinetics of a range of cationic drugs in perfused rat livers that had been treated with CCl 4 , alcohol, or were untreated (controls) using the multiple indicator dilution technique (MID) . The pharmacokinetics was then related to drug properties (log P app and pK a ) and changes in liver pathophysiology. The latter changes were estimated in terms of: 1) physiological alterations in sinusoidal morphology as expressed by changes in the mean and normalized variance of sinusoidal transit times; 2) a degree of fibrosis index determined by computer-assisted image analysis; 3) the level of intrahepatocellular proteins [e.g., ␣ 1 -acid glycoprotein (AAG) and microsomal protein]; and 4) cytochrome P450 (P450) concentrations. We anticipated that the fibrosis index (FI) might be a surrogate measure for changes in plasma membrane perme-ability due to a decreased diffusivity or an increased diffusion path length. As variations in plasma AAG content in various diseases have been used to account for the fraction unbound in plasma of many drugs (Rowland and Tozer, 1995) , we felt it was important to monitor and examine the role of AAG and other proteins in the intrahepatic disposition of drugs. The relationships between the pharmacokinetic parameters (e.g., permeability-surface area product) of a given solute and these histopathological data as well as the physicochemical properties of a solute (e.g., lipophilicity) were then defined by using stepwise regression analysis. Cationic drugs were studied in this work for four reasons: 1) they constitute 70 to 80% of all drugs; 2) they often have a limited therapeutic ratio (e.g., cardiovascular, analgesic, and psychotherapeutic drugs); 3) they constitute the majority of drugs showing a high first-pass effect; and 4) structure-hepatic disposition relationships of model cationic drugs with varying lipophilicity exist for normal rat livers.
Materials and Methods
Chemicals. Atenolol, antipyrine, prazosin, labetalol, propranolol, diltiazem, ethanol, and CCl 4 -Induced Liver Disease Rat Model. The CCl 4 rat model was established following a procedure outlined in detail previously (Proctor and Chatamra, 1982) . Briefly, male Wistar rats (weighing approximately 150 g) were placed in all-wire mesh cages in groups of eight each (two groups) and given sodium phenobarbital (35 mg/dl) (Biotech International Ltd., Rocklea, Australia) in their drinking water ad libitum; the first dose of CCl 4 was given 10 days later. Group 1 animals were given CCl 4 (Sigma-Aldrich) once a week for 12 weeks. CCl 4 was dissolved in corn oil and given by intragastric gavage without anesthetic. The initial dose of CCl 4 was 0.04 ml. Body weight was monitored daily, and each subsequent dose was adjusted by the weight loss associated with the preceding dose. All doses were multiples of the original dose, and the total volume of dose was 1.0 ml. Group 2 animals were treated identical to group 1, except that they were given a 1.0-ml dose of corn oil weekly without CCl 4 .
Alcohol-Induced Liver Disease Rat Model. The alcohol rat model was developed by using a procedure described previously (Takeyama et al., 1996) . Briefly, male Wistar rats (weighing approximately 150 g) were placed in all-wire mesh cages in groups of eight each (two groups). Group 1 rats were single fed for 12 weeks on a nutritionally liquid high-fat alcohol diet (Dyets, Bethlehem, PA) containing ethanol (36% of the total caloric intake). The intake volume of those liquid diets single fed to the rats was 100 ml/day. Group 2 animals were treated identical to group 1, except that they were given a control diet (Dyets) that contained no ethanol.
After 12 weeks, the animals were sacrificed for MID studies and histopathological examination. The Animal Ethics Committee at the University of Queensland approved all animal studies.
Liver Biochemistry Determinations. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured on a Hitachi 747 analyzer (Hitachi Ltd., Tokyo, Japan) to assess the severity of disease by taking blood samples from tail vein every fortnight.
In Situ Rat Liver Perfusions. The in situ perfused rat liver preparation used in this study has been described previously (Cheung et al., 1996; Hung et al., 2001) . Briefly, the portal vein was punctured with a 23-gauge needle and connected to a hydrostatic manometer to measure the in vivo portal venous pressure. The bile duct was cannulated with PE-10 (Clay Adams, Parsippany, NJ). The portal vein was then cannulated using a 16-gauge intravenous catheter, and the liver was perfused via this cannula with 2% bovine serum albumin MOPS buffer, which contains 15% (v/v) prewashed canine red blood cells (School of Veterinary Sciences, The University of Queensland, Brisbane, Australia) at pH 7.4, and oxygenated using a silastic tubing lung ventilated with 100% pure oxygen (BOC Gases, Brisbane, Australia). The perfusion system used was nonrecirculating and used a peristaltic pump (Cole-Parmer Instrument Co., Chicago, IL). After perfusion was effected, the animals were sacrificed by thoracotomy, and the thoracic inferior vena cava was cannulated with PE-240 (Clay Adams). The animal was placed in a temperaturecontrolled perfusion cabinet at 37°C. Liver viability was assessed by macroscopic appearance, bile production, oxygen consumption, and perfusion pressure as described by Cheung et al. (1996) .
Bolus Studies. To reflect in vivo microcirculation, perfusion was initially conducted at a rate of 15 ml/min and was then adjusted to a pressure similar to the in vivo portal venous pressure (Varin and Huet, 1985) . After a 10-min perfusion stabilization period, aliquots (50 l) of perfusion medium containing a particular cationic drug [0.06 -0.11 mol of atenolol/propranolol, 0.09 -0.15 mol of antipyrine, 0.04 -0.08 mol of prazosin/labetalol, or 0.04 -0.07 mol of diltiazem as determined by high-performance liquid chromatography (HPLC) assay], [
3 H]water (3 ϫ 10 6 dpm), and [U-14 C]sucrose (1.5 ϫ 10 6 dpm) was injected into the liver with outlet samples collected via a fraction collector over 4 min (1 s ϫ 20, 4 s ϫ 5, 10 s ϫ 5, and 30 s ϫ 5). In each liver, a maximum of six injections was made with the order of injection randomized and no repeat of the same injection in the same rat. A stabilization period of 10 min was afforded between two injections. The total perfusion time for each liver was less than 2 h. These samples were centrifuged at 1500g (25°C) for 3 min, and aliquots (100 l) of supernatant (containing [ 3 H]water and [U-
14 C]sucrose) were taken for scintillation counting using a MINAXI Beta TRI-CARB 4000 series liquid scintillation counter (Packard BioScience, Meriden, CT). The residue was vortexed and prepared for HPLC analysis to determine the outflow concentration of each cationic drug.
Analytical Procedure. The HPLC method used in this work has been described and validated previously (Hung et al., 2001 ). The within-day coefficients of variation for all the drugs studied were in the range of 0.6 to 4.4% (n ϭ 3).
Histopathological Examination. For light microscopy, three to five slices of each liver were fixed in 10% neutral buffered formalin then routinely embedded in paraffin. Five-micrometer sections were prepared and stained with H&E for histopathological examination.
Quantitation of Fibrosis. Fibrous tissue was differentially stained pink in 5-m paraffin sections by the hematoxylin van Gieson method (a solution of 1% aqueous acid fuchsin, saturated aqueous picric acid, and concentrated hydrochloric acid). The degree of fibrosis was quantified by computer-assisted image analysis (ImagePro Plus version 3.0 for Windows; Media Cybernetics, Inc., Silver Spring, MD). For each rat, the area of stained fibrous tissue in five randomly selected fields was measured, and the average was expressed as fibrosis per unit area of liver tissue (termed the FI) as described by MacIntosh et al. (1992) .
Determination of Hepatic Tissue AAG Level. Livers were harvested from the rats after MID studies and perfused with a mixed solution of calcium and magnesium-free Hanks' balanced salt solution, 5 mM EDTA, and 10 mM HEPES (all from Sigma-Aldrich) at 10 ml/min for 10 min to remove the protein and blood from sinusoidal beds. The liver (approximately 1 g) was then homogenized in 1 ml of MOPS buffer using tissue blender and centrifuged at 3000g for 10 min. A quinaldine red (Sigma-Aldrich) fluorometric titration method based on a method described previously was used for tissue AAG level analysis (Imamura et al., 1994) .
Determination of Hepatic Cytoskeleton Residue (CR), Microsomal Protein (MP), and P450 Concentrations. The liver (approximately 1 g) was homogenized in 2.5 ml of ice-cold 0.25 M sucrose containing 50 mM Tris-HCl buffer (pH 7.4) for 3 to 5 min. The homogenates were centrifuged at 5,000 rpm for 20 min, and the pellets resuspended in 2.5 ml of Tris buffer as the cytoskeleton fraction. The supernatant (approximately 1 ml) from the 5,000 rpm centrifugation was centrifuged again at 50,000 rpm for 1 h. The resulting pellets were resuspended in 2.5 ml of Tris buffer and used as the microsomal fraction. The CR and MP concentrations in the respective fractions were determined by the method of Lowry et al. (1951) . P450 content in MP was estimated from the dithionite-reduced difference spectrum of CO-bubbled samples using the molar extinction difference of 104 mM Ϫ1 cm Ϫ1 in absorption at peak position (about 450 nm) (Matsubara et al., 1976) .
Investigation of Cationic Drug Binding to Hepatic Components. These experiments were carried out in 1) blank MOPS buffer (pH 7.4); 2) buffer containing 0.35 mg/ml rat AAG (Sigma-Aldrich); 3) buffer containing 0.35 mg/ml MP from normal livers; or 4) buffer containing 0.35 mg/ml CR from normal livers. The unbound fraction of cationic drug in each buffer solution (f uT ) was estimated using an ultrafiltration method. A known concentration of the cationic drug stock solution was added to 500 l of each buffer solution to make a final concentration of 0.05 M and placed in a centrifugal filter device (Microcon YM-30; Millipore Corp., Bedford, MA) and then centrifuged at 3000g for 10 min. The ultrafiltrate (in triplicate) was assayed by HPLC. The f uT was determined as the ratio of the free concentration to total concentration of solute. Estimation of association constant K a,T (K a,AAG , K a,MP , or K a,CR ) for binding to a given hepatic component (MP, AAG, or CR) to an individual cation was deduced using
is the concentration of one of these hepatic components.
Hepatic Extraction Ratio and Mean Transit Time. Nonparametric estimates of hepatic extraction ratio (E), mean transit time (MT), and normalized variance (CV 2 ) were determined from the outflow concentration versus time profiles for the model cationic drugs as described previously (Hung et al., 2001 ). The recovery for each drug is defined by its availability, which is defined by 1 Ϫ E (Roberts and Rowland, 1986) .
Estimation of Pharmacokinetic Parameters by Modeling and Data Fitting of the Outflow Concentration-Time Profiles of Extracellular and Cellular References after Impulse Dosing.
A mixture of two inverse Gaussian density functions with correction for catheter effects was used to estimate the extracellular space (V B , determined by [U-14 C]sucrose) (Weiss et al., 1997) . A barrier-limited plus space-distributed liver model with correction for catheter effects was used to estimate the total water volume (V w , determined by [ 3 H]water), V w then being used to estimate the cellular water volume, V C , defined as (V w Ϫ V B ) .
Modeling and Data Fitting of the Outflow ConcentrationTime Profiles of Model Cationic Drugs.
A heterogeneous (barrier-limited and space-distributed) transit time model (the "two-phase stochastic model") was used to estimate the pharmacokinetic parameters of hepatocellular influx, efflux, binding, and elimination for the permeating solutes (Hung et al., 2001) . Briefly, the model (Fig. 1 ) assumes unbound drug transfer across the permeability barrier (plasma membrane) with influx and efflux rate constants k in and k out , respectively. An apparent distribution ratio (K v ) for an unbound solute between the cellular and extracellular space is defined by k in /k out . K S is the equilibrium amount ratio for slowly equilibrating binding sites as defined by an on and off rate constant (Hung et al., 2001) . K S for a given drug, in theory, should be related to the product of the association constant K a,p of the drug for protein p and the concentration of protein [P] i.e., K S ϭ K a,p ⅐ [P] (Rowland and Tozer, 1995) . The permeability-surface area product (PS) is given by k in ⅐ V B /f uB where V B is the extracellular space and f uB is the fraction unbound in the perfusate, estimated previously by Hung et al. (2001) . The intrinsic clearance, CL int , was estimated as the product of the elimination rate constant k e and the cellular distribution volume for water, V C , following the approach of Pang et al. (1995) . The stochastic approach represents the transit of a molecule through the organ as a series of sojourns in one of the two regions described by density functions. The sojourn time distribution f y (t) of a molecule after a single excursion in the cellular space for the resulting twocompartment cell model can be obtained by standard methods in the Laplace domain,f y (s) ϭ L Ϫ1 [f y (t)], as described earlier Hung et al., 2001 
The liver biochemistry differed greatly between the three animal models. The CCl 4 -treated group has a significantly higher mean ALT (1,027.40 Ϯ 778.60 IU/l) and AST (740.11 Ϯ 301.64 IU/l) level than those of the alcohol-treated (ALT, 109.60 Ϯ 13.10 IU/l and AST, 90.94 Ϯ 14.19 IU/l) and normal control (ALT, 54.00 Ϯ 7.70 IU/l and AST, 46.39 Ϯ 7.50 IU/l) groups (p Ͻ 0.001). Two other controls used in this study for completeness, CCl 4 control (phenobarbitone treatment only) and alcohol control (liquid diet only), yielded experimental parameters not significantly different than those for the normal control group (data not shown).
Histopathology. Sections of normal rat livers showed typical architecture under light microscopy, i.e., cords of hepatocytes one cell wide radiating out from hepatic venules toward portal tracts. Livers from rats fed an alcohol diet showed perivenular macrovesicular steatosis with minor fibrosis. The CCl 4 -treated livers showed severe fibrosis, and fibrosis was perivenular with venous-venous fibrous linkage. FI, estimated by computer-assisted image analysis, for each of the animal models is shown in Table 1 . The CCl 4 -treated group had a significantly higher FI value than the alcoholtreated (p Ͻ 0.05) and control groups (p Ͻ 0.001).
Hepatic AAG, MP, and P450 Concentrations. Table 1 also shows that the alcohol-treated group has a significantly higher hepatic AAG, MP, and P450 content than those of the control (AAG, p Ͻ 0.05; MP, p Ͻ 0.05; and P450, p Ͻ 0.01) and CCl 4 -treated groups (AAG, p Ͻ 0.01; MP, p Ͻ 0.001; and P450, p Ͻ 0.001). The AAG, MP, and P450 levels found in the CCl 4 control (phenobarbitone treatment only) and alcohol control (liquid diet only) were not significantly different than those for the normal controls. jpet.aspetjournals.org Downloaded from log P app are 1) MP, log f u,MP ϭ 0.098 Ϫ 0.307 log P app (p ϭ 0.001, r 2 ϭ 0.953, and n ϭ 6) and 2) AAG, log f u,AAG ϭ 0.012 ϩ 0.8 log P app (p ϭ 0.0001, r 2 ϭ 0.999, and n ϭ 6). Although both MP and AAG bind lipophilic cationic drugs (prazosin, labetalol, propranolol, and diltiazem) in hepatocytes, MP may be more dominant given its 10-fold greater concentration in the hepatocyte than AAG for all models (Table 1) .
Hepatic Extraction Ratio and Mean Transit Time. Table 2 shows that hepatic extraction ratio (E) increases with the lipophilicity (log P app ) of drug in various animal models. The CCl 4 -treated group has a significantly lower E than that of the normal control and alcohol-treated groups for the same lipophilic drug but not for the same polar drug. Interestingly, the alcohol-treated group has a significantly higher E than that of the normal control and CCl 4 -treated groups for the same lipophilic drug but not for the same polar drug. Stepwise regression analysis examining relationships between hepatic extraction ratio (E) with lipophilicity of drug (log P app ) and P450 yielded a high correlation of predicted and observed E ( Fig. 2A ; log E ϭ Ϫ0.35 ϩ 0.07 P450 ϩ 0.027 log P app ; p ϭ 0.0001, r 2 ϭ 0.932, and n ϭ 30). FI was excluded from this regression as nonsignificant. It is also poorly correlated with P450 (FI ϭ 4.082 Ϫ 3.186 P450, r 2 ϭ 0.174, and n ϭ 30). Table 2 also shows that the drug MT increases with the lipophilicity of drug in various animal models. The CCl 4 -treated group has a significantly lower MT value than that of the normal control and alcohol-treated groups for the same lipophilic drug. The CV 2 for the drugs did not appear to be related to lipophilicity in various animal models. E, MT, and CV 2 for CCl 4 control (phenobarbitone treatment only) and alcohol control (liquid diet only) obtained for the various cationic drugs was not significantly different than those for the normal controls, although there was a trend for the lipophilic drugs to show a longer MT in the CCl 4 control group (data not shown).
Modeling and Data Fitting of the Outflow Concentration-Time Profiles. Figure 1 , A and B, shows typical logarithms of normalized outflow concentration versus time data for atenolol (most hydrophilic) and diltiazem (most lipophilic) in various animal models. Also shown are the corresponding regression line fits using a heterogeneous (barrier-limited and space-distributed) transit time model and a data weighting of 1/y obs 2 . All MID data appeared to be adequately fitted by the models. The estimated model parameters for extracellular volume V B and cellular water volume V C were 1) V B ϭ 0.49 Ϯ 0.15 ml g Ϫ1 of liver, V C ϭ 1.30 Ϯ 0.44 ml g Ϫ1 of liver for the normal control group (n ϭ 6); 2) V B ϭ 0.53 Ϯ 0.19 ml g Ϫ1 of liver, V C ϭ 1.38 Ϯ 0.39 ml g Ϫ1 of liver for the alcohol-treated group (n ϭ 6); and 3) V B ϭ 0.57 Ϯ 0.21 ml g Ϫ1 of liver, V C ϭ 1.34 Ϯ 0.41 ml g Ϫ1 of liver for the CCl 4 -treated group (n ϭ 6). Although the V B obtained for the CCl 4 control (phenobarbitone treatment only) and alcohol control (liquid diet only) were similar to the normal controls, the V C for the CCl 4 control was larger (data not shown).
The pharmacokinetic parameters for each of the cationic drugs are shown in Table 3 . It is evident that K v increases with increasing pK a of the drug in the various animal models. Except for antipyrine and prazosin, the CCl 4 -treated group has a significantly lower K v than that of the alcohol-treated and normal control groups for the same drug. Table 3 also shows that CL int , PS, and K S all increase with the lipophilicity (log P app ) of drug in various animal models. The CCl 4 -treated group has a significantly lower PS, CL int , and K S than those of the alcohol-treated and normal control groups for the same lipophilic drug. The alcohol-treated group has a significantly higher CL int and K S than those of the CCl 4 -treated and normal control groups for the same lipophilic drug. In contrast, no significant differences in CL int and K S were found between normal control, CCl 4 -treated, or alcoholtreated rats for the same polar drug. The pharmacokinetic parameters found in the CCl 4 control (phenobarbitone treatment only) and alcohol control (liquid diet only) were not significantly different than those for the normal controls (data not shown). Further stepwise regression analysis examining relationships between pharmacokinetic parameters (log PS, log K S , log K v , or log CL int ) with nature of drug (log P app or pK a ) and histopathological results (FI, MP, and P450) yielded the following relationships: 1) log PS ϭ 1.647 Ϫ 0.028 FI ϩ 0.08 log P app (p ϭ 0.001, r 2 ϭ 0.844, and n ϭ 30); 2) log K S ϭ Ϫ0.017 ϩ 0.242 MP ϩ 0.022 log P app (p ϭ 0.0001, r 2 ϭ 0.926, and n ϭ 30); 3) log CL int ϭ 1.938 ϩ 0.31 P450 ϩ 0.112 log P app (p ϭ 0.011, r 2 ϭ 0.799, and n ϭ 30); and 4) log K v ϭ 0.596 Ϫ 0.021 FI ϩ 0.073 pK a (p ϭ 0.0001, r 2 ϭ 0.992, and n ϭ 30). Tables 1 and 2 show that AAG makes only a small apparent contribution to K S , e.g., 14% for propranolol in normal controls (K S,MP ϭ K a,MP ⅐ MP ϭ 218, and K S,AAG ϭ K a,AAG , AAG ϭ 32 when AAG is expressed as milligram per 
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jpet.aspetjournals.org gram liver). Also, MP may be an inappropriate determinant for CL int as P450 is less than 10% of MP in all groups.
Discussion
This work has shown that the pharmacokinetics of cationic drugs in cirrhotic livers can be related to the liver histopathology and solute physicochemical properties. Care was taken to accurately define the vascular dispersion in the liver (Roberts and Rowland, 1986 ) using a heterogeneous (barrierlimited and space-distributed) transit time model as described in our previous work (Hung et al., 2001) . In this work, robust and good fits were also found for cationic drugs in diseased rat livers (Fig. 1, A and B ). An implicit assumption in this model is linearity of kinetics as defined by hepatocellular unbound concentrations being below the Michaelis constants for the enzymes metabolizing each drug. The modeling has also assumed that a rapid equilibrium occurs between erythrocytes and the plasma, and that the efflux of the cationic drugs from erythrocytes is sufficiently rapid so as to not lead to an erythrocyte carriage effect (Goresky et al., 2000) .
The experimental parameters associated with the normal and CCl 4 -treated perfusion studies, reflecting liver viability, are also comparable with previous reports (Varin and Huet, 1985; Hung et al., 2001) . CCl 4 produces acute hepatocellular injury with centrilobular necrosis and stenosis (Hong et al., 2000) . In contrast, alcohol produces chronic hepatocellular injury with inflammation and perivenular macrovesicular steatosis (Sherlock, 1993; Takeyama et al., 1996) . These observations were confirmed in this work.
This work has shown that hepatic extraction ratio E and primary parameters PS, K S , and CL int depend on the lipophilicity of the cationic drug, irrespective of the disease state (Table 3 ). This work has also shown that a good correlation exists between the predicted and observed values for E and the parameter values (Fig. 2) . E or availability F (ϭ 1Ϫ E) can be related to f uB , PS, perfusate flow rate, and CL int in a number of models describing hepatic elimination (Pang and Rowland, 1977; Roberts and Rowland, 1986; Roberts and Anissimov, 1999; Roberts et al., 2000) , including the dual inverse Gaussian model (Weiss et al., 1998) . These models show E is related to f uB , PS, CL int , and perfusate flow rate, which are, in turn, related to log P app (f uB , PS, and CL int ), FI (PS), and P450 (CL int ). The good relationship between log E with log P app and P450 ( Fig. 2A ) is therefore consistent with the E being defined by PS, CL int , etc. A high correlation was found for E with log P app and P450 (r 2 ϭ 0.932) with the stepwise regression excluding FI as a determinant.
The underlying relationship between PS with FI and log P app is consistent with the definition of PS, namely PS ϭ K m D m S/h m , where K m is the plasma membrane-unbound perfusate concentration coefficient, D m is the solute diffusivity in the plasma membrane, S is the surface area, and h m is the membrane path length for diffusion. Hence, in the absence of transporters, K m is defined by the solute lipophilicity and log P app as a surrogate. An impaired uptake of solute across the capillarized endothelium in cirrhosis is consistent with a slower solute diffusivity and longer diffusion path length as a consequence of collagenization of the Disse space. The FI is a surrogate measure for changes in D m and h m as a determinant of PS.
The extent of solute uptake into normal and cirrhotic livers (Hung et al., 2001) .
b Fraction unbound in perfusate (Hung et al., 2001) .
c Association constant for microsomal protein from f
e Hung et al. (2001) . 
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jpet.aspetjournals.org depends on both tissue binding as well as ion trapping by organelles such as the mitochondria and lysosomes. The main measure of tissue uptake is slow binding as expressed by the equilibrium amount ratio for slowly equilibrating binding sites, K S . In this work, we found that the alcoholtreated group has the highest intrahepatocellular AAG level and MP concentration, whereas the CCl 4 -treated group has the lowest AAG level and MP concentration among various animal models (Table 1) . One source for these binding sites is the soluble microsomal proteins, MP. The regression between log K S with the determinants of the contribution of MP to K S , its association constant K a,MP (defined from in vitro binding, Table 2 ), and the concentration of MP in the liver, i.e., K S,MP ϭ K a,MP ⅐ MP is log K S ϭ 0.027 ϩ 0.618 log K a,MP ϩ 0.295 log MP (p ϭ 0.001, r 2 ϭ 0.947, and n ϭ 30). Earlier, it was shown that the unbound fraction (and thus, K a,p ) of cationic drug in perfusate or buffers containing MP or AAG also correlated with the octanol-water partition coefficient log P app . Hence, the derived expression log K S ϭ Ϫ0.017 ϩ 0.242 MP ϩ 0.022 log P app (p ϭ 0.0001, r 2 ϭ 0.926, and n ϭ 30; Fig. 2C ) suggests that hepatic tissue binding can be predicted from a knowledge of the lipophilicity of the solute as defined by log P app and binding protein content as defined by MP. As discussed earlier, AAG, one of the acute-phase proteins that increases in various conditions including inflammatory diseases (Brinkman-van der Linden et al., 1996) , has concentrations in the liver too low to make a substantial contribution to K S .
The K v , or distribution ratio of a solute between the tissue and vascular space, is mainly dependent on ion trapping in organelles and asymmetric transport across the plasma membrane (Hung et al., 2001) . We have previously shown that K v increases with drug pK a and an ion-trapping effect for cationic drugs related to the volume of and intraorganelle pH in the hepatic cytoplasm, mitochondria, and lysosomes (Hung et al., 2001) . We have now shown that K v is related to both pK a and FI, enabling a lesser dependence of K v on pK a for the alcohol-treated and, even less so, for the CCl 4 -treated group to be described. The decreased dependence is most likely due to a higher intracellular pH and a reduction in the ion trapping of the cations as a consequence of a reduction in ionization. Hence, the higher cytosolic pH in cirrhosis rats (Х7.45) than in normal rats (Х7.27), due to the activation of hepatocellular Na ϩ /H ϩ exchange in cirrhosis (Elsing et al., 1994) , would explain a lower K v for the CCl 4 -treated group relative to the normal control group as well as a loss of dependence of K v on pK a for the CCl 4 -treated group. How fibrosis affected the organelle volumes (and potential iontrapping volume) is less certain. For instance, CCl 4 -induced cirrhosis reduces rat liver mitochondrial volume (Krä henbü hl et al., 2000) (normally about 20% of hepatocyte volume; Hung et al., 2001 ) but increases the activity and numbers of lysosomes (Dufour et al., 1994 ) (normally about 1% of hepatocyte volume; Hung et al., 2001) .
In this analysis, we estimated the intrinsic metabolic clearance CL int as a product of k e and V C . This approach, used previously by Pang et al. (1995) , ensures that solutes iontrapped in organelles or bound to rapidly equilibrating binding sites are not determinants of CL int . The good correlation of observed and predicted CL int (Fig. 2D) derived from the expression log CL int ϭ 1.938 ϩ 0.31 P450 ϩ 0.112 log P app (p ϭ 0.011, r 2 ϭ 0.799, and n ϭ 30) suggests that intrinsic elimination clearance of a solute in the diseased liver can be predicted from lipophilicity of the solute and P450 activity of the liver tissue. It should be noted that P450 consists of a number of isozymes that, in response to a stimulant, may be differentially expressed. Better correlations may therefore be expected by relating CL int to the individual isozymes responsible for the metabolism of a given drug. Relevant to this work, Kono et al. (1999) showed chronic exposure to alcohol caused induction of CYP3A, CYP2A12, CYP1A, CYP2B, and CYP2E1 expression in mouse livers. Bastien et al. (2000) showed CCl 4 -induced cirrhosis was associated with reduction of CYP1A, CYP2C, CYP2E1, and CYP3A expression in rat livers. Given that P450 accounted for a low and variable fraction of MP (0.076 normal group; 0.093 alcohol-treated group; and 0.03 CCl 4 -treated group), caution should be exercised in using MP as a surrogate for P450. It is therefore apparent, as noted by Obach (1997) and McLure et al. (2000) , that much of the drug binding to MP is nonspecific and not necessarily a determinant of CL int . In summary, the disposition of cationic drugs may be directly related to the extent of fibrosis caused by the liver disease and the physicochemical properties of the drugs. The changes in the extraction ratio E are consistent with a reduction in PS, CL int , and perfusate flow rate, each of which define E. These reductions arise from alterations in sinusoidal morphology and in the hepatic microcirculation and a decreased enzymatic activity due to loss of normal metabolic zonation and microsomal activity in the liver. In addition, hepatic distribution is reduced in cirrhosis due to reduced tissue binding (lower K S ) as a consequence of a lower synthesis of intrahepatocellular proteins as well as a loss of an ion-trapping effect (lower k in /k out ) due to an elevation of intracellular pH and changes in organelle volumes. Drug lipophilicity is a key determinant of cation drug extraction. There were good correlations between the predicted and observed pharmacokinetic parameters (E, PS, K S , CL int , or K v ) of the model cationic drugs based on nature of drug (log P app or pK a ) and the histopathological results (FI, MP, and P450). This prediction of E using various determining variables such as log P app and P450 is likely to be improved by the use of larger data set (drugs and severity of disease state). These results should be relevant in better understanding how changes in fibrosis-induced hepatic diseases quantitatively affect hepatic drug pharmacokinetics and in assisting preclinical drug development through predictions of the first-pass effect.
